CD274 and hepatocellular carcinoma: Cytotoxic T lymphocyte protein 4 (CTLA-4) and programmed cell death protein-1 and its ligand (PD-1, PD-L1) are some of the immune checkpoints targeted in HCC clinical trials [16].